CBD: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
VisualWikitext
No edit summary
No edit summary
 
(10 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{TreatmentInfo
{{TreatmentInfo
|drug_name=CBD (Cannabidiol)
|drug_name=Sodium R Lipoate and Hydroxycitrate (METABLOC)
|FDA_approval=Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment
|FDA_approval=No (Used in investigational metabolic therapy for brain tumors)
|used_for=Investigational use in cancer treatment, including symptom management and potential anti-tumor effects
|used_for=Investigational use in brain tumor treatment, including primary and metastatic gliomas
|clinical_trial_phase=Preclinical studies and early human trials for cancer
|clinical_trial_phase=Early clinical evaluation in a small case series
|common_side_effects=Tiredness, diarrhea, changes in appetite/weight; generally well-tolerated at doses used for epilepsy
|common_side_effects=Not specified in the provided information
|OS_with=Not applicable; ongoing research into potential impacts on overall survival in cancer patients
|OS_with=Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis
|PFS_with=Not applicable; ongoing research into potential impacts on progression-free survival in cancer patients
|PFS_with=Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months
|usefulness_rating=4
|usefulness_rating=3
|notes=CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers,
|notes=This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.
conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.
|treatment_category=Over-the-Counter Drugs and Supplements
Recent research into the use of CBD (cannabidiol) for treating glioblastoma has shown promising results, particularly in its potential impact on overall survival (OS). One study found that CBD, due to its anti-inflammatory properties, was able to reduce the size of glioblastoma tumors and improve the tumor microenvironment. This effect could potentially enhance the efficacy of standard treatments such as radiation and chemotherapy. However, most of these results have been observed in preclinical models, and more robust human trials are required to fully understand the OS benefits.<ref name="ScienceDaily">{{Cite web |title=CBD reduces glioblastoma’s size, supportive environment in experimental model |url=https://www.sciencedaily.com/releases/2021/12/211223141935.htm |publisher=ScienceDaily |date=2021-12-23 |accessdate=2024-08-12}}</ref><ref name="MayoClinic">{{Cite web |title=Fighting glioblastoma - one of the deadliest forms of brain cancer |url=https://cancerblog.mayoclinic.org/2024/05/02/fighting-glioblastoma-one-of-the-deadliest-forms-of-brain-cancer/ |publisher=Mayo Clinic |date=2024-05-02 |accessdate=2024-08-12}}</ref>
 
Additionally, a UK-based Phase II clinical trial, known as the ARISTOCRAT trial, is currently investigating the effects of Sativex, an oral spray containing both CBD and THC, combined with chemotherapy, on patients with recurrent glioblastoma. The earlier Phase I trial suggested that this combination might extend survival, which led to the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates.<ref name="BrainTumourCharity">{{Cite web |title=Phase 2 trial of cannabis-based drug in glioblastomas to open in summer 2022 |url=https://www.thebraintumourcharity.org/news/phase-2-trial-cannabis-based-drug-glioblastomas-open-summer-2022/ |publisher=The Brain Tumour Charity |date=2022-11-25 |accessdate=2024-08-12}}</ref>
 
These studies represent a growing interest in the potential of cannabinoids as a supplementary treatment for glioblastoma, but while early results are promising, further research is essential to establish clear OS benefits.
 
|category=Nutraceuticals
|links=
|links=
|toxicity_level=2
|toxicity_level=2
|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen.
|toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.
}}
|overview=Sodium R Lipoate and Hydroxycitrate (METABLOC) is an investigational metabolic therapy for brain tumors, particularly gliomas, showing promising outcomes in early clinical evaluations, including significant tumor shrinkage and extended progression-free survival in some patients. While the therapy has a relatively low toxicity level and no severe adverse reactions reported thus far, further large-scale trials are needed to confirm its efficacy and safety.}}

Latest revision as of 01:19, 18 January 2025

Property Information
Drug Name Sodium R Lipoate and Hydroxycitrate (METABLOC)
Overview Sodium R Lipoate and Hydroxycitrate (METABLOC) is an investigational metabolic therapy for brain tumors, particularly gliomas, showing promising outcomes in early clinical evaluations, including significant tumor shrinkage and extended progression-free survival in some patients. While the therapy has a relatively low toxicity level and no severe adverse reactions reported thus far, further large-scale trials are needed to confirm its efficacy and safety.
FDA Approval No (Used in investigational metabolic therapy for brain tumors)
Used for Investigational use in brain tumor treatment, including primary and metastatic gliomas
Clinical Trial Phase Early clinical evaluation in a small case series
Clinical Trial Explanation Not specified
Common Side Effects Not specified in the provided information
OS without Not specified
OS with Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis
PFS without Not specified
PFS with Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level 2
Toxicity Explanation The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.

Notes: This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.


From Ben Williams Book: Not specified

Loading comments...
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=CBD&oldid=94188"